COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION
First Claim
Patent Images
1. An isolated antibody or antibody fragment thereof which binds to Repulsive Guidance Molecule a (“
- RGMa”
), wherein the antibody comprises a domain or region selected from the group consisting of;
(a) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
1, (b) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
5, (c) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
9, (d) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
13, (e) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
17, (f) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
21, (g) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
25, (h) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
29, (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
33, (j) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
37;
(k) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
41;
(l) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
45;
(m) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
49;
(n) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
53, (o) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
57, (p) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
61, (q) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
152, (r) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
95, (s) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
99, (t) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
103, (u) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
107, (v) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
111, (w) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
115, (x) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
119, (y) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
123, (z) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
127, (aa) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
131, (bb) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
135, (cc) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
67, (dd) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
68, (ee) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
69 (ff) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
70, (gg) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
71, (hh) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
72, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
73, (jj) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
1 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
5, (kk) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
9 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
13, (ll) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
17 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
21, (mm) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
25 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
29, (nn) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
33 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
37, (oo) a variably heavy domain comprising the amino acid sequence of SEQ ID NO;
41 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
45, (pp) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
49 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
53, (qq) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
57 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
61, (rr) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
152 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
95, (ss) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
99 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
103, (tt) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
107 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
111, (uu) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
115 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
119, (vv) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
123 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
127, (ww) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
131 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
135, (xx) a variable heavy chain comprising a complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, (yy) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
8, (zz) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
10, a CDR2 comprising the amino acid sequence of SEQ ID NO;
11, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
12, (aaa) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
14, a CDR2 comprising the amino acid sequence of SEQ ID NO;
15, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
16, (bbb) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
18, a CDR2 comprising the amino acid sequence of SEQ ID NO;
19, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
20, (ccc) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
22, a CDR2 comprising the amino acid sequence of SEQ ID NO;
23, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
24, (ddd) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
26, a CDR2 comprising the amino acid sequence of SEQ ID NO;
27, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
28, (eee) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
30, a CDR2 comprising the amino acid sequence of SEQ ID NO;
31, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
32, (fff) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
34, a CDR2 comprising the amino acid sequence of SEQ ID NO;
35, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
36, (ggg) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
38, a CDR2 comprising the amino acid sequence of SEQ ID NO;
39, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
40, (hhh) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
42, a CDR2 comprising the amino acid sequence of SEQ ID NO;
43, and CDR3 comprising the amino acid sequence of SEQ ID NO;
44;
(iii) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
46, a CDR2 comprising the amino acid sequence of SEQ ID NO;
47, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
48;
(jjj) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
50, a CDR2 comprising the amino acid sequence of SEQ ID NO;
51, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
52 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
54, a CDR2 comprising the amino acid sequence of SEQ ID NO;
55, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
56, (kkk) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
58, a CDR2 comprising the amino acid sequence of SEQ ID NO;
59, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
60, (lll) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
62, a CDR2 comprising the amino acid sequence of SEQ ID NO;
63, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
64, (mmm) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
92 or 153, a CDR2 comprising the amino acid sequence of SEQ ID NO;
93 or 154, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
94 or 155, (nnn) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
96 or 156, a CDR2 comprising the amino acid sequence of SEQ ID NO;
97 or 157, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
98 or 158, (ooo) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
100, a CDR2 comprising the amino acid sequence of SEQ ID NO;
101, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
102, (ppp) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
104, a CDR2 comprising the amino acid sequence of SEQ ID NO;
105, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
106, (qqq) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
108, a CDR2 comprising the amino acid sequence of SEQ ID NO;
109, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
110, (rrr) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
112, a CDR2 comprising the amino acid sequence of SEQ ID NO;
113, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
114, (sss) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
116, a CDR2 comprising the amino acid sequence of SEQ ID NO;
117, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
118, (ttt) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
120, a CDR2 comprising the amino acid sequence of SEQ ID NO;
121, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
122, (uuu) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
124, a CDR2 comprising the amino acid sequence of SEQ ID NO;
125, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
126, (vvv) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
128, a CDR2 comprising the amino acid sequence of SEQ ID NO;
129, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
130, (www) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
132, a CDR2 comprising the amino acid sequence of SEQ ID NO;
133, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
134, (xxx) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
136, a CDR2 comprising the amino acid sequence of SEQ ID NO;
137, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
138, (yyy) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
67, (zzz) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
68, (aaaa) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
69, (bbbb) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
70, (cccc) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
71, (dddd) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
72, (eeee) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
73, (ffff) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
8, (gggg) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
67, (hhhh) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
92 or 153, a CDR2 comprising the amino acid sequence of SEQ ID NO;
93 or 154, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
94 or 155 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
96 or 156, a CDR2 comprising the amino acid sequence of SEQ ID NO;
97 or 157, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
98 or 158, (iiii) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
100, a CDR2 comprising the amino acid sequence of SEQ ID NO;
101, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
102 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
104, a CDR2 comprising the amino acid sequence of SEQ ID NO;
105, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
106, (jjjj) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
108, a CDR2 comprising the amino acid sequence of SEQ ID NO;
109, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
110 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
112, a CDR2 comprising the amino acid sequence of SEQ ID NO;
113, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
114, (kkkk) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
116, a CDR2 comprising the amino acid sequence of SEQ ID NO;
117, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
118 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
120, a CDR2 comprising the amino acid sequence of SEQ ID NO;
121, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
122, (llll) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
124, a CDR2 comprising the amino acid sequence of SEQ ID NO;
125, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
126 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
128, a CDR2 comprising the amino acid sequence of SEQ ID NO;
129, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
130, (mmmm) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
132, a CDR2 comprising the amino acid sequence of SEQ ID NO;
133, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
134 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
136, a CDR2 comprising the amino acid sequence of SEQ ID NO;
137, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
138, (nnnn) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
68, (oooo) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
69, (pppp) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
70, (qqqq) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
71, (rrrr) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
72, (ssss) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
73, (tttt) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
10, a CDR2 comprising the amino acid sequence of SEQ ID NO;
11, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
12, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
14, a CDR2 comprising the amino acid sequence of SEQ ID NO;
15, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
16, (uuuu) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
18, a CDR2 comprising the amino acid sequence of SEQ ID NO;
19, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
20, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
22, a CDR2 comprising the amino acid sequence of SEQ ID NO;
23, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
24, (vvvv) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
26, a CDR2 comprising the amino acid sequence of SEQ ID NO;
27, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
28, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
30, a CDR2 comprising the amino acid sequence of SEQ ID NO;
31, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
32, (wwww) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
34, a CDR2 comprising the amino acid sequence of SEQ ID NO;
35, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
36, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
38, a CDR2 comprising the amino acid sequence of SEQ ID NO;
39, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
40, (xxxx) a variable heavy domain chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
42, a CDR2 comprising the amino acid sequence of SEQ ID NO;
43, and a CDR comprising the amino acid sequence of SEQ ID NO;
44, and a variable light domain chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
46, a CDR2 comprising the amino acid sequence of SEQ ID NO;
47, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
48;
(yyyy) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
50, a CDR2 comprising the amino acid sequence of SEQ ID NO;
51, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
52, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
54, a CDR2 comprising the amino acid sequence of SEQ ID NO;
55, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
56, (zzzz) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
58, a CDR2 comprising the amino acid sequence of SEQ ID NO;
59, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
60, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
62, a CDR2 comprising the amino acid sequence of SEQ ID NO;
63, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
64.
2 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.
-
Citations
47 Claims
-
1. An isolated antibody or antibody fragment thereof which binds to Repulsive Guidance Molecule a (“
- RGMa”
), wherein the antibody comprises a domain or region selected from the group consisting of;
(a) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
1, (b) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
5, (c) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
9, (d) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
13, (e) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
17, (f) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
21, (g) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
25, (h) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
29, (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
33, (j) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
37;
(k) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
41;
(l) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
45;
(m) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
49;
(n) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
53, (o) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
57, (p) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
61, (q) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
152, (r) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
95, (s) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
99, (t) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
103, (u) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
107, (v) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
111, (w) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
115, (x) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
119, (y) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
123, (z) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
127, (aa) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
131, (bb) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
135, (cc) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
67, (dd) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
68, (ee) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
69 (ff) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
70, (gg) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
71, (hh) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
72, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
73, (jj) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
1 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
5, (kk) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
9 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
13, (ll) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
17 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
21, (mm) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
25 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
29, (nn) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
33 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
37, (oo) a variably heavy domain comprising the amino acid sequence of SEQ ID NO;
41 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
45, (pp) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
49 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
53, (qq) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
57 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
61, (rr) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
152 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
95, (ss) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
99 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
103, (tt) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
107 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
111, (uu) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
115 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
119, (vv) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
123 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
127, (ww) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
131 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
135, (xx) a variable heavy chain comprising a complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, (yy) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
8, (zz) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
10, a CDR2 comprising the amino acid sequence of SEQ ID NO;
11, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
12, (aaa) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
14, a CDR2 comprising the amino acid sequence of SEQ ID NO;
15, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
16, (bbb) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
18, a CDR2 comprising the amino acid sequence of SEQ ID NO;
19, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
20, (ccc) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
22, a CDR2 comprising the amino acid sequence of SEQ ID NO;
23, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
24, (ddd) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
26, a CDR2 comprising the amino acid sequence of SEQ ID NO;
27, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
28, (eee) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
30, a CDR2 comprising the amino acid sequence of SEQ ID NO;
31, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
32, (fff) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
34, a CDR2 comprising the amino acid sequence of SEQ ID NO;
35, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
36, (ggg) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
38, a CDR2 comprising the amino acid sequence of SEQ ID NO;
39, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
40, (hhh) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
42, a CDR2 comprising the amino acid sequence of SEQ ID NO;
43, and CDR3 comprising the amino acid sequence of SEQ ID NO;
44;
(iii) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
46, a CDR2 comprising the amino acid sequence of SEQ ID NO;
47, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
48;
(jjj) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
50, a CDR2 comprising the amino acid sequence of SEQ ID NO;
51, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
52 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
54, a CDR2 comprising the amino acid sequence of SEQ ID NO;
55, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
56, (kkk) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
58, a CDR2 comprising the amino acid sequence of SEQ ID NO;
59, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
60, (lll) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
62, a CDR2 comprising the amino acid sequence of SEQ ID NO;
63, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
64, (mmm) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
92 or 153, a CDR2 comprising the amino acid sequence of SEQ ID NO;
93 or 154, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
94 or 155, (nnn) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
96 or 156, a CDR2 comprising the amino acid sequence of SEQ ID NO;
97 or 157, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
98 or 158, (ooo) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
100, a CDR2 comprising the amino acid sequence of SEQ ID NO;
101, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
102, (ppp) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
104, a CDR2 comprising the amino acid sequence of SEQ ID NO;
105, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
106, (qqq) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
108, a CDR2 comprising the amino acid sequence of SEQ ID NO;
109, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
110, (rrr) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
112, a CDR2 comprising the amino acid sequence of SEQ ID NO;
113, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
114, (sss) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
116, a CDR2 comprising the amino acid sequence of SEQ ID NO;
117, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
118, (ttt) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
120, a CDR2 comprising the amino acid sequence of SEQ ID NO;
121, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
122, (uuu) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
124, a CDR2 comprising the amino acid sequence of SEQ ID NO;
125, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
126, (vvv) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
128, a CDR2 comprising the amino acid sequence of SEQ ID NO;
129, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
130, (www) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
132, a CDR2 comprising the amino acid sequence of SEQ ID NO;
133, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
134, (xxx) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
136, a CDR2 comprising the amino acid sequence of SEQ ID NO;
137, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
138, (yyy) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
67, (zzz) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
68, (aaaa) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
69, (bbbb) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
70, (cccc) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
71, (dddd) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
72, (eeee) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
73, (ffff) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
8, (gggg) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
67, (hhhh) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
92 or 153, a CDR2 comprising the amino acid sequence of SEQ ID NO;
93 or 154, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
94 or 155 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
96 or 156, a CDR2 comprising the amino acid sequence of SEQ ID NO;
97 or 157, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
98 or 158, (iiii) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
100, a CDR2 comprising the amino acid sequence of SEQ ID NO;
101, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
102 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
104, a CDR2 comprising the amino acid sequence of SEQ ID NO;
105, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
106, (jjjj) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
108, a CDR2 comprising the amino acid sequence of SEQ ID NO;
109, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
110 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
112, a CDR2 comprising the amino acid sequence of SEQ ID NO;
113, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
114, (kkkk) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
116, a CDR2 comprising the amino acid sequence of SEQ ID NO;
117, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
118 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
120, a CDR2 comprising the amino acid sequence of SEQ ID NO;
121, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
122, (llll) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
124, a CDR2 comprising the amino acid sequence of SEQ ID NO;
125, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
126 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
128, a CDR2 comprising the amino acid sequence of SEQ ID NO;
129, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
130, (mmmm) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
132, a CDR2 comprising the amino acid sequence of SEQ ID NO;
133, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
134 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
136, a CDR2 comprising the amino acid sequence of SEQ ID NO;
137, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
138, (nnnn) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
68, (oooo) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
69, (pppp) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
70, (qqqq) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
71, (rrrr) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
72, (ssss) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
73, (tttt) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
10, a CDR2 comprising the amino acid sequence of SEQ ID NO;
11, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
12, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
14, a CDR2 comprising the amino acid sequence of SEQ ID NO;
15, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
16, (uuuu) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
18, a CDR2 comprising the amino acid sequence of SEQ ID NO;
19, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
20, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
22, a CDR2 comprising the amino acid sequence of SEQ ID NO;
23, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
24, (vvvv) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
26, a CDR2 comprising the amino acid sequence of SEQ ID NO;
27, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
28, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
30, a CDR2 comprising the amino acid sequence of SEQ ID NO;
31, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
32, (wwww) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
34, a CDR2 comprising the amino acid sequence of SEQ ID NO;
35, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
36, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
38, a CDR2 comprising the amino acid sequence of SEQ ID NO;
39, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
40, (xxxx) a variable heavy domain chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
42, a CDR2 comprising the amino acid sequence of SEQ ID NO;
43, and a CDR comprising the amino acid sequence of SEQ ID NO;
44, and a variable light domain chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
46, a CDR2 comprising the amino acid sequence of SEQ ID NO;
47, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
48;
(yyyy) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
50, a CDR2 comprising the amino acid sequence of SEQ ID NO;
51, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
52, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
54, a CDR2 comprising the amino acid sequence of SEQ ID NO;
55, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
56, (zzzz) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
58, a CDR2 comprising the amino acid sequence of SEQ ID NO;
59, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
60, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
62, a CDR2 comprising the amino acid sequence of SEQ ID NO;
63, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
64. - View Dependent Claims (2, 4, 5, 7, 9, 11, 25, 26, 28, 29, 30, 37, 44)
- RGMa”
-
3. (canceled)
-
6. (canceled)
-
8. (canceled)
-
10. (canceled)
-
12. (canceled)
-
13. (canceled)
-
14. (canceled)
-
15. (canceled)
-
16. (canceled)
-
17. (canceled)
-
18. (canceled)
-
19. (canceled)
-
20. (canceled)
-
21. (canceled)
-
22. (canceled)
-
23. (canceled)
-
24. (canceled)
-
27. (canceled)
-
31. A method for determining whether a subject has a neurite degenerative disorder, comprising
(a) measuring the level of RGMa in a sample from the subject; - and
(b) comparing the level of RGMa in the sample with a normal control, wherein an altered level of RGMa indicates that the subject has a neurite degenerative disorder. - View Dependent Claims (32, 33, 34)
- and
- 35. The method of claim 35, wherein the immunoassay is an enzyme-linked immunosorbent assay (ELISA).
-
38. (canceled)
-
39. (canceled)
-
40. (canceled)
-
41. (canceled)
-
42. (canceled)
-
43. (canceled)
-
45. An isolated antibody or antibody fragment thereof which binds to Repulsive Guidance Molecule a (“
- RGMa”
), wherein the antibody or antibody fragment comprises a variable heavy domain that comprises three complementarity-determining regions (CDR) corresponding to the following formulas, respectively;Xaa1-Xaa2-Xaa3-Xaa4-Xaa5 (Formula 1-CDR-H1), wherein Xaa1 is an amino acid selected from the group consisting of S, D, E, N, G, and T;
Xaa2 is an amino acid selected from the group consisting of H, Y, L, S, and Q;
Xaa3 is an amino acid selected from the group consisting of G, D, A, T, and Y;
Xaa4 is an amino acid selected from the group consisting of I, M, and W; and
Xaa5 is an amino acid sequence from the group consisting of S, N, H, A, T, and Q;Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-(Xaa)n (Formula 2-CDR-H2), wherein n is 0 or 1, and wherein Xaa1 is an amino acid selected from the group consisting of Y, V, A, G, L, G, S, and N;
Xaa2 is an amino acid selected from the group consisting of I, M, and F;
Xaa3 is an amino acid selected from the group consisting of S, N, D, F, and Y;
Xaa4 is an amino acid selected from the group consisting of P, Y, G, W, H, A, and S;
Xaa5 is an amino acid selected from the group consisting of Y, N, D, E, S, K, G, and T;
Xaa6 is an amino acid selected from the group consisting of S, G, D, T, and N;
Xaa7 is an amino acid selected from the group consisting of G, S, I, E, N, and R;
Xaa8 is an amino acid selected from the group consisting of N, L, R, S, T, and Y;
Xaa9 is an amino acid selected from the group consisting of T, K, G, N, I, and Y;
Xaa10 is an amino acid selected from the group consisting of N, G, Y, T, and K;
Xaa11 is an amino acid selected from the group consisting of Y, F, N, and H;
Xaa12 is an amino acid selected from the group consisting of A, T, V, P, L, and S;
Xaa13 is an amino acid selected from the group consisting of Q, D, P, and S;
Xaa14 is an amino acid selected from the group consisting of K, S, N, and L;
Xaa15 is an amino acid selected from the group consisting of L, F, V, K, and R;
Xaa16 is an amino acid selected from the group consisting of Q, K, R, and S; and
Xaa17 is a glycine; andXaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-(Xaa)n (Formula 3-CDR-H3), wherein n is 0-11, and wherein Xaa1 is an amino acid selected from the group consisting of V, S, E, N, L, D, Q, and A;
Xaa2 is an amino acid selected from the group consisting of G, T, R, Y, L, I, D, and S;
Xaa3 is an amino acid selected from the group consisting of S, V, D, G, F, Y, P, M, C, L, and A;
Xaa4 is an amino acid selected from the group consisting of G, L, Y, N, E, K, A, and F;
Xaa5 is an amino acid selected from the group consisting of P, S, Y, A, V, G, T, E, and W;
Xaa6 is an amino acid selected from the group consisting of Y, V, S, L, D, G, H, and P;
Xaa7 is an amino acid selected from the group consisting of Tyr, Asp, Gly, Ser, Phe, Leu, and Cys;
Xaa8 is an amino acid selected from the group consisting of Tyr, Lys, Asp, Ala, and Gln;
Xaa9 is an amino acid selected from the group consisting of Met, Glu, Phe, Leu, Ser, Thr, Pro, and Tyr;
Xaa10 is an amino acid selected from the group consisting of Asp, Gly, Tyr, Ser, Leu, His, and Phe;
Xaa11 is an amino acid selected from the group consisting of Val, Tyr, Leu, His, Gly, Trp, and Asp;
Xaa12 is an amino acid selected from the group consisting of Tyr and Phe;
Xaa13 is an amino acid selected from the group consisting of Tyr, Gly, and Asp;
Xaa14 is an amino acid selected from the group consisting of Ala, Leu, Pro, and Tyr;
Xaa15 is an amino acid selected from the group consisting of Met, Leu, and Phe;
Xaa16 is an amino acid selected from the group consisting of Asp and Gly; and
Xaa17 is an amino acid selected from the group consisting of an Val, Asp, and Tyr.
- RGMa”
-
46. An isolated antibody or antibody fragment thereof which binds to Repulsive Guidance Molecule a (“
- RGMa”
), wherein the antibody or antibody fragment comprises a variable light domain that comprises three complementarity-determining regions (CDR) corresponding to the following formulas, respectively;Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-(Xaa)n (Formula 1-CDR-L1), wherein n is 0-3, and wherein Xaa1 is an amino acid selected from the group consisting of T, S, R, G, and Q;
Xaa2 is an amino acid selected from the group consisting of G, L, and A;
Xaa3 is an amino acid selected from the group consisting of T, D, S, N and A;
Xaa4 is an amino acid selected from the group consisting of S, K, G, Q, N, and E;
Xaa5 is an amino acid sequence from the group consisting of S, L, G, I, D, and P;
Xaa6 is an amino acid selected from the group consisting of S, G, N, H, and I;
Xaa7 is an amino acid selected from the group consisting of V, D, I, S, G and H;
Xaa8 is an amino acid selected from the group consisting of G, K, A, S, I, N, T, and D;
Xaa9 is an amino acid selected from the group consisting of D, Y, A, C, S, and F;
Xaa10 is an amino acid selected from the group consisting of S, A, G, L, V, and N;
Xaa11 is an amino acid selected from the group consisting of I, C, Y, H, R, N, and S;
Xaa12 is an amino acid selected from the group consisting of Tyr, Gly, Ala, and Val;
Xaa13 is an amino acid selected from the group consisting of Val, and Asn; and
Xaa14 is an amino acid selected from the group consisting of Ser and His;Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-(Xaa)n (Formula 2-CDR-L2), wherein n is 0-4, and wherein Xaa1 is an amino acid selected from the group consisting of D, Q, G, V, Y, S and E;
Xaa2 is an amino acid selected from the group consisting of V, D, N, and A;
Xaa3 is an amino acid selected from the group consisting of T, S, Y, N, and K;
Xaa4 is an amino acid selected from the group consisting of K, N, D, Q and T;
Xaa5 is an amino acid selected from the group consisting of R, G, S, and L;
Xaa6 is an amino acid selected from the group consisting of P, S, I, and E;
Xaa7 is an amino acid selected from the group consisting of S, H, I, and T;
Xaa8 is Asn;
Xaa9 is Lys; and
Xaa10 is Gly;
Xaa11 is Asp; andXaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-(Xaa)n (Formula 3-CDR-L3), wherein n is 0-2, and wherein Xaa1 is an amino acid selected from the group consisting of C, Q, H, F, H, L, V, I, K, Y, and A;
Xaa2 is an amino acid selected from the group consisting of S, A, T, Q, and V;
Xaa3 is an amino acid selected from the group consisting of Y, W, and S;
Xaa4 is an amino acid selected from the group consisting of A, D, G, S, H and Y;
Xaa5 is an amino acid selected from the group consisting of G, S, N, P, D, V, and T;
Xaa6 is an amino acid selected from the group consisting of I, T, S, G, L, F and Y;
Xaa7 is an amino acid selected from the group consisting of D, T, L, I, P, and S;
Xaa8 is an amino acid selected from the group consisting of T, G, R, Y, D, N, W, L, F and P;
Xaa9 is an amino acid selected from the group consisting of L, V, G, T, and H;
Xaa10 is an amino acid selected from the group consisting of Val, Tyr, and His;
Xaa11 is Leu or Val.
- RGMa”
-
47. An isolated antibody or antibody fragment thereof which binds to Repulsive Guidance Molecule a (“
- RGMa”
), wherein the antibody or antibody fragment comprises a variable heavy domain that comprises three complementarity-determining regions (CDR-H1, H2, and H3) corresponding to the following formulas, respectively;Xaa1-Xaa2-Xaa3-Xaa4-Xaa5 (Formula 1-CDR-H1), wherein Xaa1 is an amino acid selected from the group consisting of S, D, E, N, G, and T;
Xaa2 is an amino acid selected from the group consisting of H, Y, L, S, and Q;
Xaa3 is an amino acid selected from the group consisting of G, D, A, T, and Y;
Xaa4 is an amino acid selected from the group consisting of I, M, and W; and
Xaa5 is an amino acid sequence from the group consisting of S, N, H, A, T, and Q;Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa 12-Xaa13-Xaa14-Xaa15-Xaa16-(Xaa)n (Formula 2-CDR-H2), wherein n is 0 or 1, and wherein Xaa1 is an amino acid selected from the group consisting of Y, V, A, G, L, G, S, and N;
Xaa2 is an amino acid selected from the group consisting of I, M, and F;
Xaa3 is an amino acid selected from the group consisting of S, N, D, F, and Y;
Xaa4 is an amino acid selected from the group consisting of P, Y, G, W, H, A, and S;
Xaa5 is an amino acid selected from the group consisting of Y, N, D, E, S, K, G, and T;
Xaa6 is an amino acid selected from the group consisting of S, G, D, T, and N;
Xaa7 is an amino acid selected from the group consisting of G, S, I, E, N, and R;
Xaa8 is an amino acid selected from the group consisting of N, L, R, S, T, and Y;
Xaa9 is an amino acid selected from the group consisting of T, K, G, N, I, and Y;
Xaa10 is an amino acid selected from the group consisting of N, G, Y, T, and K;
Xaa11 is an amino acid selected from the group consisting of Y, F, N, and H;
Xaa12 is an amino acid selected from the group consisting of A, T, V, P, L, and S;
Xaa13 is an amino acid selected from the group consisting of Q, D, P, and S;
Xaa14 is an amino acid selected from the group consisting of K, S, N, and L;
Xaa15 is an amino acid selected from the group consisting of L, F, V, K, and R;
Xaa16 is an amino acid selected from the group consisting of Q, K, R, and S; and
Xaa17 is a glycine; andXaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-(Xaa)n (Formula 3-CDR-H3), wherein n is 0-11, and wherein Xaa1 is an amino acid selected from the group consisting of V, S, E, N, L, D, Q, and A;
Xaa2 is an amino acid selected from the group consisting of G, T, R, Y, L, I, D, and S;
Xaa3 is an amino acid selected from the group consisting of S, V, D, G, F, Y, P, M, C, L, and A;
Xaa4 is an amino acid selected from the group consisting of G, L, Y, N, E, K, A, and F;
Xaa5 is an amino acid selected from the group consisting of P, S, Y, A, V, G, T, E, and W;
Xaa6 is an amino acid selected from the group consisting of Y, V, S, L, D, G, H, and P;
Xaa7 is an amino acid selected from the group consisting of Tyr, Asp, Gly, Ser, Phe, Leu, and Cys;
Xaa8 is an amino acid selected from the group consisting of Tyr, Lys, Asp, Ala, and Gln;
Xaa9 is an amino acid selected from the group consisting of Met, Glu, Phe, Leu, Ser, Thr, Pro, and Tyr;
Xaa10 is an amino acid selected from the group consisting of Asp, Gly, Tyr, Ser, Leu, His, and Phe;
Xaa11 is an amino acid selected from the group consisting of Val, Tyr, Leu, His, Gly, Trp, and Asp;
Xaa12 is an amino acid selected from the group consisting of Tyr and Phe;
Xaa13 is an amino acid selected from the group consisting of Tyr, Gly, and Asp;
Xaa14 is an amino acid selected from the group consisting of Ala, Leu, Pro, and Tyr;
Xaa15 is an amino acid selected from the group consisting of Met, Leu, and Phe;
Xaa16 is an amino acid selected from the group consisting of Asp and Gly; and
Xaa17 is an amino acid selected from the group consisting of an Val, Asp, and Tyr; andwherein the antibody or antibody fragment also comprises a variable light domain that comprises three complementarity-determining regions (CDR-L1, L2, and L3) corresponding to the following formulas, respectively; Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-(Xaa)n (Formula 1-CDR-L1), wherein n is 0-3, and wherein Xaa1 is an amino acid selected from the group consisting of T, S, R, G, and Q;
Xaa2 is an amino acid selected from the group consisting of G, L, and A;
Xaa3 is an amino acid selected from the group consisting of T, D, S, N and A;
Xaa4 is an amino acid selected from the group consisting of S, K, G, Q, N, and E;
Xaa5 is an amino acid sequence from the group consisting of S, L, G, I, D, and P;
Xaa6 is an amino acid selected from the group consisting of S, G, N, H, and I;
Xaa7 is an amino acid selected from the group consisting of V, D, I, S, G and H;
Xaa8 is an amino acid selected from the group consisting of G, K, A, S, I, N, T, and D;
Xaa9 is an amino acid selected from the group consisting of D, Y, A, C, S, and F;
Xaa10 is an amino acid selected from the group consisting of S, A, G, L, V, and N;
Xaa11 is an amino acid selected from the group consisting of I, C, Y, H, R, N, and S;
Xaa12 is an amino acid selected from the group consisting of Tyr, Gly, Ala, and Val;
Xaa13 is an amino acid selected from the group consisting of Val, and Asn; and
Xaa14 is an amino acid selected from the group consisting of Ser and His;Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-(Xaa)n (Formula 2-CDR-L2), wherein n is 0-4, and wherein Xaa1 is an amino acid selected from the group consisting of D, Q, G, V, Y, S and E;
Xaa2 is an amino acid selected from the group consisting of V, D, N, and A;
Xaa3 is an amino acid selected from the group consisting of T, S, Y, N, and K;
Xaa4 is an amino acid selected from the group consisting of K, N, D, Q and T;
Xaa5 is an amino acid selected from the group consisting of R, G, S, and L;
Xaa6 is an amino acid selected from the group consisting of P, S, I, and E;
Xaa7 is an amino acid selected from the group consisting of S, H, I, and T;
Xaa8 is Asn;
Xaa9 is Lys; and
Xaa10 is Gly;
Xaa11 is Asp; andXaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-(Xaa)n (Formula 3-CDR-L3), wherein n is 0-2, and wherein Xaa1 is an amino acid selected from the group consisting of C, Q, H, F, H, L, V, I, K, Y, and A;
Xaa2 is an amino acid selected from the group consisting of S, A, T, Q, and V;
Xaa3 is an amino acid selected from the group consisting of Y, W, and S;
Xaa4 is an amino acid selected from the group consisting of A, D, G, S, H and Y;
Xaa5 is an amino acid selected from the group consisting of G, S, N, P, D, V, and T;
Xaa6 is an amino acid selected from the group consisting of I, T, S, G, L, F and Y;
Xaa7 is an amino acid selected from the group consisting of D, T, L, I, P, and S;
Xaa8 is an amino acid selected from the group consisting of T, G, R, Y, D, N, W, L, F and P;
Xaa9 is an amino acid selected from the group consisting of L, V, G, T, and H;
Xaa10 is an amino acid selected from the group consisting of Val, Tyr, and His;
Xaa11 is Leu or Val.
- RGMa”
Specification